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Background: Drug-resistance and therapy failure due to drug-drug interactions are the main challenges in current
treatment against Human Immunodeficiency Virus (HIV) infection. As such, there is a continuous need for the
development of new and more potent anti-HIV drugs. Here we established a high-throughput screen based on the
highly permissive TZM-bl cell line to identify novel HIV inhibitors. The assay allows discriminating compounds
acting on early and/or late steps of the HIV replication cycle.
Results: The platform was used to screen a unique library of secondary metabolites derived from myxobacteria.
Several hits with good anti-HIV profiles were identified. Five of the initial hits were tested for their antiviral potency.
Four myxobacterial compounds, sulfangolid C, soraphen F, epothilon D and spirangien B, showed EC50 values in
the nM range with SI > 15. Interestingly, we found a high amount of overlapping hits compared with a previous
screen for Hepatitis C Virus (HCV) using the same library.
Conclusion: The unique structures and mode-of-actions of these natural compounds make myxobacteria an
attractive source of chemicals for the development of broad-spectrum antivirals. Further biological and structural
studies of our initial hits might help recognize smaller drug-like derivatives that in turn could be synthesized and
further optimized.Introduction
Current Human Immunodeficiency Virus (HIV) treat-
ment comprises a combination of three or more anti-
retroviral drugs, which often lead to drug-resistance and
therapy failure due to drug-drug interactions and toxic
effects, especially in patients with HIV-associated co-
infections [1-5]. As such, there is a continuous need for
the development of new and more potent anti-HIV
drugs. Here we describe the establishment of a two-step
high-throughput screening (HTS) platform to identify
molecules against HIV infection. The assay is based on
the highly permissive TZM-bl cell line [6]. These are
modified HeLa cells expressing endogenous CD4,
CXCR4 and CCR5 receptors, and an integrated Tat-* Correspondence: andreas.meyerhans@upf.edu
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reproduction in any medium, provided the ordependent firefly luciferase gene. The TZM-bl cells in
combination with HIV pseudoviruses have been exten-
sively used in antibody neutralization tests with highly
reproducible results [7] and in a previous siRNA screen
[8]. Upon infection, the viral RNA genome is reversed
transcribed into DNA and integrated into the host-cell
as a provirus. Then, the proviral-produced Tat protein
mediates the activation of the LTR-driven luciferase
gene. Thus, the amount of luciferase signal is in direct
relationship with the efficiency of infection and the anti-
viral activity of test compounds can be measured as a
function of reductions in luciferase expression compared
to un-treated or drug-solvent controls.
The two-step cell-based screen is shown in Figure 1
and described in Materials and Methods. Briefly, TZM-
bl cells seeded in 384-well plates are incubated with test
compounds and infected with HIVLAI at a multiplicity of
infection (MOI) of 0.5. To monitor compound-related
toxicity in parallel, TZM-bl cells are left uninfected andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Overview of the HIV screen assay. (A) Two step infection approach used for the primary screen. In Part 1, TZM-bl cells are seeded on
384-well plates, incubated with the test compounds for 2 h and infected with HIV. 48 h post-infection, supernatants from infected cells are used
to infect fresh TZM-bl cells (beginning of Part 2). Cells from Part 1 are assayed for Tat-dependent luciferase expression and, in parallel, for
compound-related toxicity. 48 h after re-infection, cells of Part 2 are assayed in the same manner (See text for details). (B) Scheme showing the
possible outcomes of the two-step HIV screen. A compound inactive against HIV will not show significant reductions in Tat-dependent luciferase
expression compared to solvent controls for both Part 1 and Part 2 of the screen (left). A compound truly acting on early steps of the HIV cycle
will show reductions in luciferase expression in Part 1 that will be reflected in Part 2 of the screen (middle). A compound acting on late events
might show little or no decrease in relative luciferase in Part 1, but it will show a significant reduction of luciferase expression in cells assayed in
Part 2.
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48 h after initial infection, virus-containing supernatants
are used to infect fresh TZM-bl cells (Part 2) and cells
from Part 1 are assayed for Tat-dependent luciferase
expression (Figure 1A). Compound-related toxicity is
quantified in parallel plates by a commercial ATP assay.
48 h after re-infection of fresh TZM-bl cells (part 2 of
the screen), plates are assayed as in part 1. This ap-
proach is able to identify molecules acting on early HIV
steps (from entry to translation) by detecting luciferase
reductions in cells from Part 1, and compounds acting
on late HIV steps (such as trafficking, assembly, release
and maturation), which will be detected in re-infectedcells of Part 2 of the screen (Figure 1B). The assay set-
up is similar to a previous anti-HIV assay using MAGI
cells [9]. The effects of test compounds on infectivity
and cell viability are quantified by normalizing the mean
luciferase expression units to the solvent controls and
hits are determined by calculating a robust Z-score as
described [9] (see Materials and Methods).
Results and discussion
To validate the two-step screen, we tested the effect of
three FDA-approved anti-HIV drugs: the nucleoside
reverse transcriptase inhibitor Zidovudine, the fusion
inhibitor Enfuvirtide and the protease inhibitor Indinavir
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assay yielded an excellent separation between solvent
and drug controls (assay Z-factor of 0.9) [10]. The plat-
form was then used to screen a small library of around
150 myxobacterial secondary metabolites from the
Helmholtz Centre for Infection Research, Braunschweig,
Germany [11,12]. Myxobacteria are among the top pro-
ducers of natural products, matching those produced by
marine bacteria [13]. These true microbial cell factories
are known to manufacture highly active antimicrobials
with novel chemical structures [14,15]. The library was
screened using a single concentration of each test sub-
stance (and solvent controls) assayed in quadruple.
Robust Z-score values were calculated from the mean of
the replicates as described [9,16], and plotted against the
% mean of the solvent controls. Hits are defined as com-
pounds inhibiting 50% infectivity with Z-scores < 0 and,
conversely, compounds having less than 70% toxic
effects with Z-scores > 0 (Figure 2B-D).
After discarding compounds without significant antiviral
and/or toxic effects, we analyzed hit ranking by comparing
their infectivity and viability Z-scores for both Part 1 and
Part 2 of the screen (Figure 3). Among the top hits
(i.e compounds having infectivity Z-scores < -1) in Part 1,
we found clustering of derivatives of the tubulin
polymerization inhibitors disorazoles, polyketides isolatedFigure 2 Screen validation and hit identification. (A) The screen protoc
Enfuvirtide (T20) and Indinavir (IND). Values are plotted as % mean luciferas
myxobacterial library screen are shown for Viability (B), infectivity Part 1 (C)
of the control is plotted vs. the calculated robust Z-score. Hits are defined
(infectivity Z-score < 0) and with less than 30% compound-related toxicity (
quadruple measurements.from Sorangium cellulosum [17], and tubulysins, unusual
peptides isolated from Archangium gephyra [18]. In the
primary screen both compounds inhibited HIV by 80 - 90%
with infectivity and viability Z-scores of < -1.3 and > 0,
respectively (Table 1). The tubulin polymerization en-
hancers epothilones, macrolides isolated from Sorangium
cellulosum [19], were also found among the strongest
inhibitors in Part 1 of the screen (Figure 3 and Table 1).
Other hits were the ATPase inhibitors apicularen and
archazolid [18]. Due to their known function, compounds
spirangien B and soraphen F were the most interesting hits
from Part 1 of the screen. Spirangien B is an inhibitor of
IkBα, a key regulator of the NF-κB signaling pathway [20].
Repressing IkBα has been also shown to inhibit HIV in
Jurkat cells [21]. Soraphens are acetyl-CoA carboxylate
inhibitors [22]. This enzyme is also suggested to play a role
in HIV infection [23] and other viruses requiring fatty acids
for replication [24].
In order to further analyse the results of the primary
screen, we performed dose-response assays in TZM-bl
cells with five of the initial hits and calculated their
Selectivity Index (SI), i.e. antiviral potency, based on
their respective effective concentration 50 (EC50) and
cytotoxic concentration 50 (CC50). As shown in Figure 4
and Table 2 the non-nucleoside reverse transcriptase
inhibitor Nevirapine, used as control, produced anti-HIVol was validated with the known HIV inhibitors Zidovudine (AZT),
e expression relative to solvent controls. (B-D) The results of the
and re-infection Part 2 (D). For each test compound, the % mean RLU
as compounds inhibiting HIV by at least 50% of the untreated controls
viability Z-score > 0) (blue boxes). Error bars are standard deviations of
Figure 3 Summary of the strongest myxobacterial hits. The plot shows the viability Z-score vs. the infectivity Z-score of compounds having
the strongest antiviral activity (Z score < -1) for both Part 1 and Part 2 (inlay). The figure shows a clear clustering of compounds based on
structural similarities and known function (right). The commercial drugs AZT, T20 and IND are included as positive controls. Compounds are
abbreviated to prevent figure congestion. Corresponding compound names are given in Table 1.
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myxobacterial compounds sulfangolid C and soraphen F
showed EC50 and CC50 values comparable to each other,
with SI ranging from 16 to 20. Both epothilon D and
spirangien B showed lower EC50 values than Nevirapine,
while spirangien exhibited the highest SI value of the five
tested myxobacteria metabolites (>50) (Figure 4 and
Table 2). Kulkenon was not selective in the follow-up, with
a low SI of around 5.
The most interesting hit from Part 2 of the screen was
rhizopodin, an actin inhibitor isolated from the myxo-
bacterium Myxococcus stipitatus [26]. Actin filaments
are known to be essential for virological synapse forma-
tion and HIV cell-to-cell transmission, the main route
of HIV infection in naïve cells in vivo [27,28]. Another
hit was leupyrrin B1, a macrodiol with a unique pyrrole
ring that has been shown to inhibit DNA, RNA and pro-
tein synthesis in yeast [29] (Figure 3 and Table 1). Inter-
estingly, highly substituted pyrroles have been shown to
target the HIV reverse transcriptase [30] and, in our pri-
mary screen, leupyrrin B1 also showed a mild effect on
Part 1 (data not shown). However, the studies needed to
test the real potency of these late-acting hits are beyond
this report.
In summary, we have established a two-step HTS plat-
form based on the TZM-bl cell line for the screening of
novel HIV inhibitors. The advantage of this method is that
it can distinguish between compounds acting on early or
late events of the HIV replication cycle so that initial hints
on the mode-of-action can be already obtained from
primary screens. With this assay, a small library ofsecondary metabolites derived from myxobacteria was
screened and interesting primary hits were found. In gen-
eral, the intrinsic antiviral potency was lower in the
follow-up experiments. Unfortunately, these observations
are common in HTS campaings, from which few initial
hits are confirmed in subsequent assays [31,32]. In par-
ticular, comparative low SI values have been commonly
observed for natural products of diverse origin [33-38],
and it has also been noted that a compound´s biological
efficacy is not due to in vitro toxicity when the SI > 10
[39]. In our experiments, even when dose response assays
with five of the initial hits showed a rather low SI com-
pared to a standard FDA-approved drug, four com-
pounds exhibited SI values >15. The screening for
natural compounds allows for the discovery of mole-
cules with good effectiveness, which could be further
optimized by synthetic methods. The myxobacteria sec-
ondary metabolism comprises compounds with large
chemical components that might “mask” the actual anti-
viral pharmacophore (see structures in Table 2). There-
fore, further structural studies of our initial hits might
help recognize smaller drug-like derivatives that in turn
could be synthesized and further optimized.
Conclusions
We have established a robust high-throughput anti-HIV
assay that allows, already from the primary screen, to
discriminate compounds acting on early and/or late steps
of the virus replication cycle. We identified several second-
ary metabolites derived from myxobacteria with good
anti-HIV profiles. Remarkably, compared to a previous
Table 1 Robust Z-score ranking of the myxobacterial hits for both part 1 (upper) and part 2 (bottom) of the screen
Hits from part 1 Infectivity Viability
Name Abbr. Z-score % Mean SD Z-score % Mean SD
Tubulysin l* Tlsl −2.47 3.70 1.27 −0.08 92.04 4.38
Kulkenon Kulk −2.41 5.15 1.09 0.03 93.01 18.62
Epothilon A* EpoA −2.38 0.49 0.15 0.24 87.72 10.27
Spirangien B SpiB −2.38 1.09 0.19 0.08 85.71 4.14
Epothilon C* EpoC −2.37 0.54 0.14 −0.25 81.63 4.07
Epothilon D* EpoD −2.37 1.52 0.54 1.00 97.33 11.03
Terrestribisamid A TerA −2.35 6.70 0.26 0.34 95.99 10.58
Enfuvirtide (Control) T20 −2.30 2.26 0.18 1.36 97.21 0.05
Sulfangolid C SulfC −2.29 8.13 1.26 1.73 109.20 13.03
Zidovudine (Control) AZT −2.24 4.29 0.21 1.59 98.62 1.59
Apicularen B* ApiB −1.93 13.77 2.40 −0.16 82.77 4.37
Disorazol A4* DszA4 −1.78 20.37 2.01 0.21 94.79 14.99
Tubulysin B* TlsB −1.61 24.04 1.01 0.38 89.55 10.43
Disorazol B1* DszB1 −1.55 25.89 3.60 1.25 104.59 15.96
Disorazol E1* DszE1 −1.54 26.22 3.20 −0.13 91.48 18.83
Stigmatelin A StgA −1.43 29.56 2.80 −0.34 80.43 3.79
Tubulysin A* TlsA −1.42 29.95 4.87 −0.11 83.33 9.78
Archazolid A* ArcA −1.40 30.47 4.01 −0.35 80.30 4.86
Tubulysin G* TlsG −1.34 32.46 3.73 0.34 88.98 2.54
Soraphen F SorphF −1.32 31.43 7.72 1.58 107.80 6.05
Disorazol E3* DszE3 −1.31 31.74 4.50 −0.05 92.32 3.12
Maltepolid B MalB −1.16 35.34 8.71 −0.11 91.76 7.42
Crocacin A CroA −1.06 41.32 6.39 0.15 86.66 2.43
Noricumazol B NoricB −1.01 43.03 6.34 0.86 95.47 5.54
Socein A SoceinA −0.97 40.09 7.31 0.68 99.20 13.69
Hits from part 2 Infectivity Viability
Name Abbr. Z-score % Mean SD Z-score % Mean SD
Rhizopodin A RhiA −2.11 0.00 0.00 −1.38 67.39 11.37
Indinavir (control) IND −1.93 2.73 0.10 1.43 91.21 8.50
Leupyrrin B1 LeuB1 −1.85 3.12 0.24 −0.01 67.54 11.23
Crocapeptin B* CrpB −1.80 11.38 1.78 −1.40 67.17 6.95
Soraphen A SorA −1.49 22.24 2.69 0.15 86.61 6.68
Cruentaren A CruA −1.25 31.05 5.38 0.66 93.01 5.04
Corresponding % relative infectivity and cell viability is shown. Compounds are listed by infectivity Z-scores. Control drugs are shown for comparison.
*: Compounds with anti-HCV activities according to [40].
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we found a high amount of overlapping hits (Table 1 and
[40]), suggesting that these compounds may target com-
monly used host factors or pathways necessary for viral
replication. Although the intrinsic antiviral potency of
most of these compounds remains to be elucidated, the
unique structures and mode-of-actions of these natural
compounds make myxobacteria an attractive source of
chemicals for the development of broad-spectrum
antivirals [14].Materials and methods
Cells and culture medium
TZM-bl, a modified HeLa cell-line susceptible to infection
with different HIV-1 isolates, was obtained from the NIH
AIDS Research and Reference Reagent Program, Cat#
8129) and maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Karlsruhe, Germany)
supplemented with 10% heat-inactivated FCS, HEPES
25 mM and 0.5% gentamycin. PM1 cells (NIH AIDS Re-
search and Reference Reagent Program, Cat# 3038) were
Figure 4 Dose response curves of five of the HIV hits. TZM-bl cells were pre-incubated with 10-fold serial dilutions of compounds and
vehicle control for 2 h and infected with HIVLAI at an MOI = 0.5. 48 h after initial infection luciferase expression was quantified (see Materials and
Methods). Cell toxicity was measured in parallel plates. Curves show the drug dose vs. the response normalized to the control. Error bars are
standard error of the mean.
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heat-inactivated FCS and 1% of penicillin-streptomycin.
Both cell-lines were cultured at 37°C, 5% CO2.
Virus stocks and infections
HIV-1LAI isolate was obtained from the Centre for AIDS
Reagents, NIBSC, UK. Virus was propagated in PM1 cells
and titrated in TZM-bl cells as described [41]. 1 mL
aliquots of virus stocks were stored at -80°C until use.
Infection experiments in TZM-bl cells were performed in
quadruple at a multiplicity of infection (MOI) of 0.5. For
drug-response assays TZM-bl cells were plated (104 cells/
well) in Nunc® MicroWell 96 well optical bottom plates
(Sigma) and incubated for 1 h with increasing concentra-
tions of test compounds in 10-fold dilutions or with the
corresponding vehicle (DMSO or MeOH) as negative con-
trol in triplicates. After drug incubation, cells were
infected with HIVLAI and 48 h after infection luciferase
activity was measured using Britelite Plus™ (PerkinElmer,Waltham, USA). In parallel, cell viability of TZM-bl cells
was determined with an ATP quantification method using
the commercial kit CellTiter-Glo® Luminescent Cell Via-
bility Assay (Promega, Madison, USA). ATP is a marker of
the presence of metabolically active cells [42]. Therefore,
the ATP levels relative to the untreated control are a
measure of drug-induced cytotoxicity. Mean luciferase
values were normalized to untreated controls and Effective
Concentration 50 (EC50) and Cytotoxic Concentration 50
(CC50) were calculated in GraphPad Prism (GraphPad
Software, San Diego, CA, USA) by analyzing the logdose vs.
normalized response. The Selectivity Index (SI) refers to
the antiviral potency of a drug and is calculated as the
ratio of CC50 to EC50 [43,44].
Test compounds
The library of 154 myxobacterial secondary metabolites
used for the screening belongs to a collection of natural
compounds isolated at the Helmholtz Centre for Infection
Table 2 Compound names, structures, EC50, CC50 and SI values for five of the preliminary hits
Compound name Structure EC50 (μM) CC50 (μM) SI*
Nevirapine 0.07 81.8 >1000
Sulfangolid C 0.41 8.18 20.2
Soraphen F 0.30 5.02 16.5
Epothilon D 0.0005 0.012 24.4
Spirangien B 0.007 0.35 52
Kulkenon 0.07 0.36 5.3
*SI: Selectivity Index.
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of > 95% purity as measured by LC-MS were provided in
96-well screening plates in a concentration of 1 mM
in puriss.p.a. dimethyl sulfoxide (DMSO) or methanol
(MeOH). The fusion inhibitor Enfuvirtide (Fuzeon, Roche,
Basel Switzerland) and the nucleoside reverse transcript-
ase inhibitor Zidovudine (NIH AIDS Research and Refer-
ence Reagent Program, Cat# 3485) were used as positive
controls at final concentrations of 1 μM.
Two-step TZM-bl based high-throughput screening assay
For the Part 1 of the screen, TZM-bl cells were seeded in
384-well plates at a density of 2500 cells per well in 30 μLof culture medium and incubated overnight at 37°C and
5% CO2. After incubation, 50 to 70 nL of the test com-
pounds and DMSO and/or MeOH controls from the
96-well screening plates were dispensed in quadruple to
the cells with the PinTool of an Evolution P3 pipetting
platform (PerkinElmer, Zaventem, Belgium). Final concen-
tration of compounds was around 1.5 to 2 μM with a
content of around 0.2% of DMSO or MeOH in all cases.
DMSO or MeOH alone were used as controls. 2 h after
addition of compounds, cells were infected with 50 μL of
HIVLAI at a MOI of 0.5. In parallel, duplicate plates
were left uninfected for quantification of compound-
related toxicity. Plates were incubated at 37°C and 5% CO2.
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from cells of Part 1 was transferred to fresh TZM-bl cells
seeded in 384-wells the day before. Cells of Part 1 plates
were assayed for Tat-dependent luciferase expression by
adding an equal volume of Britelite Plus™ (PerkinElmer,
Waltham, USA) according to the manufacturer´s in-
structions. Compound-related toxicity in duplicate plates
was quantified with the CellTiter-Glo® Luminescent Cell
Viability Assay (Promega, Madison, USA) according to
the manufacturer´s instructions. ATP is a marker of the
presence of metabolically active cells [42]. Following the
same procedure, cells from Part 2 of the screen were
assayed forty-eight hours after supernatant addition. Lu-
ciferase expression was measured with a TECAN Infinite
M1000PRO microplate reader (Tecan, Switzerland). The
possible outcomes of the screen are depicted in Figure S1.
Data analysis and statistics
Data was analyzed by obtaining the % mean luciferase
values normalized to solvent controls (% control mean
RLU) and by calculating the assay Z-factor (a measure
for assay quality) and samples (robust) Z-scores (a meas-
ure of hit quality) as described [9,10,16]. Briefly, back-
ground levels were substracted from the mean luciferase
of samples and values were normalized to those of the
solvent controls (set to 100% expression). The assay
Z-factor was calculated by dividing 3X standard devia-
tions of controls by the sum of their means as described
(see Table 1 in [10]). For hit determination, we adapted a
previously described robust Z-score calculation [9] to
adjust for interplate variation by dividing the absolute
deviation of the mean of the quadruple data points
(4 wells for each compound) by the median absolute
deviation of each plate. Unless stated otherwise, errors
are given as ± SD.
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